Renal Cancer

GM-CSF, IL-6 Boost Efficacy of Autologous Tumor Cell Vaccine

Published in Cancer Weekly, July 31st, 2001

by N.R. Saltmarsh, staff medical writer - Mice with established renal cell carcinoma (Renca) tumors achieved complete remission after immunization with an autologous Renca vaccine genetically enhanced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6), say researches working in Japan.

Y. Kinoshita and colleagues introduced and expressed murine GM-CSF and murine IL-6 genes in Renca cells, then subcutaneously injected Balb/c mice with either inactivated wild-type Renca, Renca-GM-CSF, Renca-IL-6, or a mixture of Renca-GM-CSF and Renca-IL-6. One to three weeks later, they challenged the mice with wild-type Renca cells.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry